Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-25-028452
Filing Date
2025-08-01
Accepted
2025-08-01 21:09:54
Documents
1
Period of Report
2025-07-30

Document Format Files

Seq Description Document Type Size
1 FORM 4 form4.html 4  
1 FORM 4 form4.xml 4 3325
  Complete submission text file 0001140361-25-028452.txt   4929
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Issuer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 6TH FLOOR NEW YORK NY 10018
Business Address
Venker Eric (Reporting) CIK: 0001801917 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40782 | Film No.: 251177782